A detailed history of Northern Trust Corp transactions in Entrada Therapeutics, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 190,309 shares of TRDA stock, worth $3.13 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
190,309
Previous 199,342 4.53%
Holding current value
$3.13 Million
Previous $2.82 Million 4.0%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$11.85 - $16.45 $107,041 - $148,592
-9,033 Reduced 4.53%
190,309 $2.71 Million
Q1 2024

May 14, 2024

SELL
$11.58 - $17.0 $15,586 - $22,882
-1,346 Reduced 0.67%
199,342 $2.82 Million
Q4 2023

Feb 13, 2024

SELL
$11.36 - $16.99 $49,677 - $74,297
-4,373 Reduced 2.13%
200,688 $3.03 Million
Q3 2023

Nov 13, 2023

BUY
$13.61 - $18.01 $149,260 - $197,515
10,967 Added 5.65%
205,061 $3.24 Million
Q2 2023

Aug 11, 2023

BUY
$11.02 - $18.01 $1.77 Million - $2.89 Million
160,701 Added 481.24%
194,094 $2.94 Million
Q1 2023

May 15, 2023

SELL
$9.58 - $16.2 $9,263 - $15,665
-967 Reduced 2.81%
33,393 $484,000
Q4 2022

Feb 13, 2023

BUY
$13.52 - $22.89 $58,987 - $99,869
4,363 Added 14.54%
34,360 $464,000
Q3 2022

Nov 14, 2022

BUY
$9.65 - $15.76 $131,905 - $215,423
13,669 Added 83.72%
29,997 $473,000
Q2 2022

Aug 12, 2022

SELL
$5.49 - $12.94 $405,875 - $956,654
-73,930 Reduced 81.91%
16,328 $199,000
Q1 2022

May 13, 2022

BUY
$7.99 - $16.93 $86,092 - $182,420
10,775 Added 13.56%
90,258 $847,000
Q4 2021

Feb 08, 2022

BUY
$13.7 - $35.0 $1.09 Million - $2.78 Million
79,483 New
79,483 $1.36 Million

Others Institutions Holding TRDA

About Entrada Therapeutics, Inc.


  • Ticker TRDA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 31,368,500
  • Market Cap $516M
  • Description
  • Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in precli...
More about TRDA
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.